Brief: Day One Announces Topline Data From Pivotal Phase 2 Firefly-1 Trial Demonstrating Meaningful Responses With Tovorafenib In Recurrent Or Progressive Pediatric Low-Grade Glioma

Day One Biopharmaceuticals

08/01/2023 22:04

Jan 8 (Reuters) - Day One Biopharmaceuticals Inc
 DAWN.O :
    * DAY ONE ANNOUNCES TOPLINE DATA FROM PIVOTAL PHASE 2
FIREFLY-1
TRIAL DEMONSTRATING MEANINGFUL RESPONSES WITH TOVORAFENIB
(DAY101) IN RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA
    * NEW DRUG APPLICATION SUBMISSION PLANNED FOR FIRST HALF OF
2023

Source text for Eikon:  ID:nGNX4lTDjf 
Further company coverage:  DAWN.O 
 ((Reuters.briefs@thomsonreuters.com;))